Seres Therapeutics, Inc. (NASDAQ: MCRB) will present at the virtual Chardan Microbiome Medicines Summit on Monday, March 16 at 8:15 a.m. ET.

Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seres Therapeutics announces a conference call and live audio webcast on May 7, 2020 to discuss first quarter 2020 results and a business update.

Seres Therapeutics announces a virtual webcast symposium focused on SER-109 on Wednesday, May 27, 2020 from 8:30 to 9:30 a.m. ET.

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.85% and 11.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics announces the appointment of Paul Biondi to its Board of Directors.

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 3.45% and 2.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics reports first quarter 2020 financial results and provides an operational update.

Q4 2019 Seres Therapeutics Inc Earnings Call

It's nice to see the Seres Therapeutics, Inc. (NASDAQ:MCRB) share price up 21% in a week. But that doesn't change the...

Is Seres Therapeutics Inc (NASDAQ:MCRB) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their […]

Seres Therapeutics provides statement on a safety alert from the U.S. Food and Drug Administration related to use of fecal microbiota transplantation.

Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Q1 Earnings conference call. During the last several years, Seres has been working hard to advance a new treatment modality with our microbiome therapeutics platform.

Seres Therapeutics (MCRB), a microbiome therapeutics platform company, has reported Q1 earnings results that fell below Street expectations. First quarter GAAP EPS of -$0.28, missed by $0.02, while revenue of $8.19M (+11.9% Y/Y) missed by $0.35M.Seres ended 1Q20 with $75.1 mm in cash and equivalents, down from $94.8 mm at end 4Q19. This is sufficient to fund “operating expenses and capital expenditure requirements, excluding net cash flows from future business development activities or potential incoming milestone payments” into 2Q21, says the company.On the impact of Covid-19, Seres announced “the timing of SER-287 Phase 2b and SER-401 Phase 1b clinical readouts is uncertain”, with no anticipated “disruptions to the availability of its drug product candidates for ongoing studies.”Ser-287 is a microbiome therapy designed to improve the signs and symptoms associated with Ulcerative Colitis (UC), while Ser-401 aims to modify immunological activity and improve checkpoint inhibitor therapy responses.Investors are also keeping a close eye on the phase III ECOSPOR III trial of Breakthrough Therapy Designated SER-109 in preventing recurrent C. difficile infection (rCDI).“Even with Covid-19-related uncertainties on SER-287 and SER-401, we continue to see 2020 as a catalyst rich year for Seres on the ECOSPOR III results alone,” writes Chardan Capital analyst Gbola Amusa. His $12.50 price target indicates shares could more than double from the $4.59 current share price.“Positive results could lead to SER-109 becoming the first FDA-approved microbiome medicine” says Amusa, noting that the current MCRB market cap is still modest in relation to the company’s pipeline.He is now looking out for a webcast investor event focusing on the Ser-109 program on May 27 and top-line data from the phase III ECOSPOR III trial in rCDI in mid-2020. In addition Seres plans to initiate a 2020 patient dosing trial in Australia and New Zealand in ulcerative colitis (UC) and initiate a Ser-155 phase Ib trial in protection from, among other things, gastrointestinal infections.Overall the stock shows a bullish Strong Buy consensus from the Street, with all four analysts saying ‘buy.’ The $9 average analyst price target indicates significant upside potential of 88%, despite shares already rallying 33% year-to-date. (See Seres Therapeutics stock analysis on TipRanks).Related News: Pfizer Sets Wheels In Motion For Covid-19 Vaccine Production Ramp AstraZeneca-Merck Ovarian Cancer Treatment Gets FDA Approval Quidel’s Rapid Covid-19 Antigen Test Scores Emergency FDA Approval More recent articles from Smarter Analyst: * Bluebird Prices New Shares At $55, Seeks To Raise $500 Million * Dynavax Explodes 40% In Pre-Market On Phase 1 Covid-19 Vaccine News * GameStop Pops 5% Amid ‘Significant Progress’ On Turnaround Plan * Carvana Sinks 7% In Pre-Market On Public Offering Of 5M Shares

Dr. Lisa von Moltke joins as CMO of Seres with an extensive career that includes senior leadership positions at Alkermes and Sanofi Genzyme.

Last week, you might have seen that Seres Therapeutics, Inc. (NASDAQ:MCRB) released its full-year result to the...

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

Seres Therapeutics completes enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III.

Q1 2020 Seres Therapeutics Inc Earnings Call

Seres Therapeutics reported fourth quarter and full year 2019 financial results and provided an operational update.